ArticleTherapeutic advances in gastroenterology2025

Efficacy and safety of Risankizumab for moderate-to-severe Crohn's disease: first Asian real-world data (STAR trial).

Chen-Shuan Chung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.